Targeting The Biology Of Aging With mTOR Inhibitors
Research Summary
A review of what rapamycin and related mTOR inhibitors do to lifespan and healthspan in mice, what the human trials completed so far show, and which new molecules might inhibit mTORC1 more selectively.
Who Or What Was Studied?
A review of published research rather than a new experiment: wild-type and disease-model mice from the NIA Interventions Testing Program and at least ten other laboratories, marmosets and companion dogs, cell and tissue work on mTORC1 and mTORC2 signalling, and clinical trials in older adults, transplant recipients and cancer patients.
What Did The Research Show?
- Across mouse studies from multiple groups and in inbred, outbred and genetically heterogeneous strains, rapamycin extended lifespan in one or more dosing groups in every study, with females typically benefiting more than males at the same dose.
- Rapamycin still extended lifespan when treatment began at 20 months of age (roughly 60 human years), and also when given intermittently or for short periods.
- The evidence separates the two complexes: mTORC2 inhibition reduces lifespan and produces glucose intolerance, insulin resistance and hyperlipidaemia, whereas the mTORC1-selective inhibitor DL001 did not cause those metabolic effects in mice.
- In older adults, 6 weeks of low-dose everolimus (0.5 mg daily or 5 mg weekly, n = 218) improved the antibody response to influenza vaccination, and a 264-person trial reported fewer infections with everolimus plus BEZ235.
- A phase 2b trial (n = 652) of low-dose BEZ235 reduced laboratory-confirmed respiratory tract infections (odds ratio 0.601, 90% CI 0.39-0.92), but the phase 3 trial (n = 1051) did not reduce clinically symptomatic respiratory illness (odds ratio 1.07, 90% CI 0.80-1.42).
Limitations And Interpretation
- It is a review, not a trial: no new human outcome is reported, and no mTOR inhibitor has been shown to slow human ageing.
- Both authors disclose financial interests in companies developing mTOR inhibitors, which the paper states openly.
- The completed human trials measured vaccine response or infection rates over weeks, not lifespan, frailty or disease incidence.
- Lifespan-extending doses in mice cannot be converted directly into human doses because of differences in bioavailability, half-life, metabolism and tissue distribution.
Summary prepared from the published paper (abstract and full text where accessible). This is not medical advice — always consult the original publication.